Structure’s oral GLP-1 a ‘work in progress’ following Phase IIa obesity and diabetes data – Endpoints News

Phase IIa da­ta for Struc­ture Ther­a­peu­tics’ oral GLP-1 drug can­di­date for type 2 di­a­betes and obe­si­ty best­ed an­a­lyst ex­pec­ta­tions on safe­ty and tol­er­a­bil­i­ty, but low­er-than-hoped-for ef­fi­ca­cy re­sults set it up for more work in the next round of test­ing in 2024.

The San Fran­cis­co biotech’s once-dai­ly oral can­di­date, GS­BR-1290, is be­ing test­ed in peo­ple with obe­si­ty and type 2 di­a­betes. It plans to kick off Phase IIb tri­als in the sec­ond half of 2024 to try and stake its place in the fast-mov­ing race to be the next gen­er­a­tion of drugs af­ter Eli Lil­ly’s Zep­bound and No­vo Nordisk’s We­govy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.